According to the World Cancer Day the key cancer facts are that 10 million people die from cancer every year, at least one third of common cancers are preventable, cancer is the second-leading cause of death worldwide, 70% of cancer deaths occur in low-to-middle income countries, millions of lives could be saved each year by implementing strategies for prevention, early detection and treatment, and the total annual economic cost of cancer is estimated at $ 1.16 trillion. For all the above reasons, AI and ML techniques are breaking into cancer research and oncology, where the potential applications are vast, and include early detection and diagnosis of cancer, subtype classification of cancer, optimisation of cancer treatment and identification of new therapeutic targets. In particular, AI is predicted to change cancer health care by advancing clinical research and drug development. And besides cutting costs, improving trial quality and reducing trial times by almost half, AI is predicted to find novel cancer biomarkers and gene signatures, recruit eligible clinical trial patients in minutes and read volumes of text in seconds. Moreover, breakthrough discoveries involving new diagnostic tools for cancer have seen AI as a major player. The phrase "prevention is better than cure" is often attributed to the Dutch philosopher Desiderius Erasmus in around 1500, but prevention is now synonym to "it's cheaper too", since preventing future illnesses and complications is vital to the future sustainability of health systems and households as well.

Were you unable to attend Transform 2022? Check out all of the summit sessions in our on-demand library now! Investments in AI-enabled healthcare have exploded over the past few years. But even with belt-tightening in 2022, digital health startups using artificial intelligence (AI) have received a whopping $3 billion in funding. That has left plenty of room for startup AI companies to make their mark in healthtech, biotech and medtech.

Atomwise is a leading artificial intelligence (AI) drug discovery company, based in San Francisco, CA. We created our EXAct computation-first, AI-driven drug discovery engine to efficiently and repeatedly engineer small molecules to improve human health and agricultural productivity. Along the way, we are solving some of the most challenging problems at the intersection of machine learning, AI, data science, and chemical/biological sciences. Do you like to work on hard problems where your solutions will have an impact? We are looking for a hands-on Director or Senior Director level scientist to lead our Machine Learning & AI research group.

This report presents before you a thorough and detailed study of the Artificial Intelligence Market. The Artificial Intelligence report comprises various company profiles of leading market players of Artificial Intelligence market.

Atomwise is one of the top artificial intelligence companies to use AI engines for transforming drug discovery.

So far, the pharmaceutical industry has contributed more to the well-being of humanity than any other industry. But lately its business model has been under significant pressure since the return on R&D investment has dropped to its lowest level in decades (lack of innovation amid digital disruption, rapid technological advances and other issues such as lack of data reproducibility) and its public reputation in US and around the world (anti vaccine movement in Europe) is worse than ever. This worrisome mix of little growth potential and low reputation is the main reason why investors are increasingly worried, not to mention that the current drug development process needs a big dose of digital innovation to deal with its messy data. As a matter of fact, Stefan Oelrich member of the Board Management of Bayer AG, President Pharmaceuticals, wrote in an article -- that the title perfectly summarises the AI pharma situation "Artificial Intelligence - When we Suddenly Know What we Don't Know" -- the following: "As we open the first doors in this unknown land we start to discover how much more is out there for our entire pharmaceutical value chain spanning from research to product supply. I expect AI to help us know what we have not known so far. Artificial Intelligence will become instrumental in our search for new medicines to better serve patients around the world as we leverage Science For A Better Life".

Wayne State University School of Medicine scientist Zhibing Zhang, M.D., Ph.D., has been selected to receive the Artificial Intelligence Molecular Screen Award from Atomwise. Atomwise contributes both AI technology and physical molecules to labs around the world. "Atomwise Inc. is a leader in using Artificial Intelligence for drug screening and design. It is great honor for our team and Wayne State University to receive this award," Dr. Zhang said. Dr. Zhang is an associate professor of Physiology, and of Obstetrics and Gynecology with the School of Medicine's C.S. Mott Center for Health and Human Development.

When you're a young male, you spend your money on cheap booze, hard drugs, and fast women – and the rest you waste. As you enter old age, you increase your spending on drugs, the type needed to treat the chronic problems you developed from abusing your body so much during your youth. The end result is more than $1.2 trillion spent last year on drugs produced by the pharmaceutical industry. Drugs are big business, but investing in biotech stocks is extremely risky due to the regulatory risks involved, the uncertainty around a drug's efficacy and safety, and the cost of taking a drug candidate to market which a pharmaceutical company incurs whether the drug gets approved or not. From an investor's perspective, it's best to find a "pick and shovel" business model somewhere in the pharma food chain that makes money regardless of whether or not drugs make it past human trials.

With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions. Now the company has raised $123 million in new funding to accelerate its business. "Scaling the technology and scaling the team and scaling what we've been doing with it," says chief executive officer Abe Heifets when asked about what comes next for the eight-year-old business. Atomwise has already signed contracts worth $5.5 billion with corporate partners that include Eli Lilly & Co., Bayer, Hansoh Pharmaceuticals and Bridge Biotherapeutics. Smaller, earlier-stage companies like StemoniX and SEngine Precision Medicine are also using Atomwise's tech.

Late one January afternoon, British pharmacologist Peter Richardson ran out of his home office and told his wife, "Got it!" She asked what he was talking about and offered a cup of tea. Richardson explained that he had identified a drug that might help people infected with a new virus spreading in China. Richardson's dash was prompted by a finding from artificial intelligence software developed by his employer, BenevolentAI, a London startup where he is vice president of pharmacology. The company has created a kind of search engine on steroids that combines drug industry data with nuggets gleaned from scientific research papers.